LOGO-ZEROLMC-peqLOGO-ZEROLMC-peqLOGO-ZEROLMC-peqLOGO-ZEROLMC-peq
  • Conócenos
    • Historia
    • Equipo
    • Patronos
    • Domicilio Fiscal
    • Estatutos
      • Constitución Fundación
      • Actualización cargos
  • Nuestras publicaciones
    • Congresos
    • Articulos científicos
    • Guías
    • Jornadas
  • Otras publicaciones
    • Guías internacionales
    • COVID-19
    • LMC y otras Neoplasias Hematológicas
  • Donaciones
  • Novedades
    • Próximos eventos
    • Actualidad LMC

 

  • Is COVID-19 less severe in CML patients than in those with other haematological cancers?
  • A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic
  • Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis
  • Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms
  • Blurring of vision as the only symptom in an undiagnosed case of chronic myeloid leukemia in the COVID-19 era
  • The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
  • COVID-19-Induced Pancytopenia in a Major Molecular Response CML Patient on Dasatinib: A Case Report and Review of the Literature. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875585/pdf/2233-1-19580-1-10-20210112.pdf
  • Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938919/pdf/mjhid-13-1-e2021022.pdf
  • Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493657/pdf/fonc-10-01428.pdf
  • Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217438/pdf/fpsyt-12-679932.pdf
  • Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239833/pdf/BJH-9999-0.pdf
  • Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. https://doi.org/10.1177/1078155220953198
  • Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301058/
  • Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341464/
  • COVID-19 in Persons With Chronic Myeloid Leukaemia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233329/
  • SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202347/
  • Leucemia Mieloide Crónica & Coronavirus COVID19 . https://aelemic.org/leucemia-mieloide-cronica-coronavirus-covid19/ COVID-19 en paciente hematológico
LOGO-ZEROLMC-peq

FUNDACION ESPAÑOLA PARA LA CURACION DE LA LEUCEMIA MIELOIDE CRONICA

Todos los derechos reservados. Zero LMC ©.
      Este sitio web usa cookies para mejorar su experiencia de navegación. Seguir navegando por el sitio web significa que aceptas nuestra política de cookies.AceptarPolítica de cookies